
ASND
Ascendis Pharma A/S
$240.64
-$6.42(-2.60%)
51
Overall
20
Value
66
Tech
68
Quality
Market Cap
$14.75B
Volume
397.11K
52W Range
$156.56 - $250.74
Target Price
$291.88
Company Overview
| Mkt Cap | $14.75B | Price | $240.64 |
| Volume | 397.11K | Change | -2.60% |
| P/E Ratio | -39.0 | Open | $245.19 |
| Revenue | $363.6M | Prev Close | $247.05 |
| Net Income | $-378.1M | 52W Range | $156.56 - $250.74 |
| Div Yield | N/A | Target | $291.88 |
| Overall | 51 | Value | 20 |
| Quality | 68 | Technical | 66 |
No chart data available
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest News
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)
TipRanks Auto-Generated Intelligence Newsdesk•8 days ago
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
TipRanks Auto-Generated Newsdesk•13 days ago
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
TipRanks Auto-Generated Newsdesk•13 days ago
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND)
TipRanks Auto-Generated Intelligence Newsdesk•16 days ago
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Becton Dickinson (BDX)
Catie Powers•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $240.64 | -2.6% | 397.11K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |